Autografting in chronic myeloid leukemia.
Autografting (or autologous stem cell transplant [ASCT]) followed by "rescue" with Philadelphia chromosome (Ph)-negative hematopoietic progenitor cells (HPC) remains a good procedure to guarantee prolonged survival for patients mobilized and autografted soon after diagnosis. Among 50 autografted patients who were treated with interferon alpha (IFN-alpha) and imatinib (for cytogenetic relapse after IFN-alpha), 41 are alive at a median of 51 months (range, 8 to 106 months). Twenty-eight (56%) patients maintain major cytogenetic remission after ASCT + IFN-alpha +/- imatinib. Such results are probably better than those achieved by IFN-alpha alone and are similar to the best results obtained in younger patients after allografting with human leukocyte antigen (HLA)-identical sibling donors. The integration of imatinib, during the coming years, into an autografting procedure could represent important progress towards developing a cure for chronic myeloid leukemia (CML) patients who cannot undergo conventional allografting.
Carella
Angelo M
AM
Department of Hematology/Oncology, IRCCS, Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo (FG), Italy.
Beltrami
Germana
G
Corsetti
Maria T
MT
D000970:Antineoplastic Agents / Q000627:therapeutic use; D024221:Antineoplastic Protocols; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D036102:Peripheral Blood Stem Cell Transplantation / Q000379:methods*; D012074:Remission Induction / Q000379:methods; D014182:Transplantation, Autologous
D000970:Antineoplastic Agents